A detailed history of Rhenman & Partners Asset Management Ab transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 58,278 shares of IMCR stock, worth $1.72 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
58,278
Previous 58,278 -0.0%
Holding current value
$1.72 Million
Previous $1.98 Million 8.15%
% of portfolio
0.15%
Previous 0.2%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$33.78 - $63.75 $726,270 - $1.37 Million
-21,500 Reduced 26.95%
58,278 $1.98 Million
Q1 2024

May 14, 2024

SELL
$60.14 - $75.36 $270,630 - $339,120
-4,500 Reduced 5.34%
79,778 $5.19 Million
Q4 2023

Feb 13, 2024

SELL
$42.85 - $69.5 $214,250 - $347,500
-5,000 Reduced 5.6%
84,278 $5.76 Million
Q3 2023

Nov 13, 2023

SELL
$49.5 - $66.6 $530,739 - $714,085
-10,722 Reduced 10.72%
89,278 $4.63 Million
Q3 2023

Nov 09, 2023

BUY
$49.5 - $66.6 $530,739 - $714,085
10,722 Added 12.01%
100,000 $5.19 Million
Q2 2023

Aug 11, 2023

SELL
$48.54 - $61.64 $2.04 Million - $2.59 Million
-42,010 Reduced 32.0%
89,278 $5.35 Million
Q1 2023

May 11, 2023

SELL
$46.12 - $65.71 $862,997 - $1.23 Million
-18,712 Reduced 12.47%
131,288 $6.49 Million
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $373,400 - $574,400
10,000 Added 7.14%
150,000 $8.57 Million
Q2 2022

Aug 12, 2022

SELL
$25.46 - $37.72 $775,817 - $1.15 Million
-30,472 Reduced 17.88%
140,000 $5.22 Million
Q1 2022

May 13, 2022

BUY
$18.94 - $34.29 $1.52 Million - $2.76 Million
80,472 Added 89.41%
170,472 $5.1 Million
Q2 2021

Aug 13, 2021

BUY
$32.22 - $41.5 $2.9 Million - $3.74 Million
90,000 New
90,000 $3.52 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.29B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.